US2024009178A1PendingUtilityA1

Treatment of pain and neurological conditions

Assignee: BIOCORRX PHARMACEUTICALS INCPriority: Dec 1, 2020Filed: Sep 21, 2023Published: Jan 11, 2024
Est. expiryDec 1, 2040(~14.3 yrs left)· nominal 20-yr term from priority
A61K 31/4468A61P 25/36A61P 3/04A61P 9/12A61P 25/30A61P 25/18A61P 25/16A61P 25/14A61P 25/00A61P 23/00A61P 25/24A61P 25/04A61K 31/485
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure is directed toward uses of compound 1 (or its stereoisomers) and compositions and/or dosage forms containing compound 1:or a pharmaceutically acceptable salt thereof. Some uses of Compound 1 and/or its stereoisomers include treating a variety of diseases and disorders, including pain, depression, and schizophrenia. In some embodiments, Compound 1 and/or its stereoisomers may be useful in the treatment of a substance use disorder while inducing fewer withdrawal symptoms than a standard-of-care opioid addiction treatment.

Claims

exact text as granted — not AI-modified
1 . A method of treating a disease or disorder, comprising administering compound 1 to a human being in need thereof, wherein compound 1 is represented by the formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is pain, depression, schizophrenia, obesity or weight-gain, or a substance use disorder; wherein for the treatment of a substance use disorder, compound 1 reverses intoxication or reduces cravings for an addictive substance other than alcohol while inducing fewer withdrawal symptoms than a standard-of-care opioid addiction treatment. 
     
     
         2 . The method of  claim 1 , wherein the disease or disorder is pain. 
     
     
         3 . The method of  claim 2 , wherein compound 1 is administered without an opioid. 
     
     
         4 . The method of  claim 1 , wherein the disease or disorder is depression. 
     
     
         5 . The method of  claim 1  wherein the disease or disorder is schizophrenia. 
     
     
         6 . The method of  claim 1 , wherein the disease or disorder is obesity or weight-gain. 
     
     
         7 . A method of  claim 1 , wherein the disease or disorder is a substance use disorder, wherein compound 1 induces fewer withdrawal symptoms than a standard-of-care opioid addiction treatment. 
     
     
         8 . The method of  claim 7 , wherein the substance use disorder is addiction to a pain medication. 
     
     
         9 . The method of  claim 7 , wherein the substance use disorder is addiction to an opioid. 
     
     
         10 . The method of  claim 9 , wherein the opioid is carfentanil, oxymorphone, hydromorphone, Percocet, tramadol, meperidine, codeine, fentanyl, heroin, morphine, oxycodone, hydrocodone, propoxyphene, methadone, meperidine, nalbuphine, pentazocine, butorphanol, or a combination thereof. 
     
     
         11 . The method of  claim 7 , wherein the standard-of-care opioid addiction treatment is buprenorphine, methadone, naloxone, or naltrexone. 
     
     
         12 . The method of  claim 7 , wherein the standard-of-care opioid addiction treatment is naloxone or naltrexone. 
     
     
         13 . The method of  claim 1 , wherein about 0.01 mg to about 1000 mg of compound 1 is released or administered daily to the human being in need thereof. 
     
     
         14 . The method of  claim 13 , wherein about 1 mg to about 400 mg of compound 1 is released or administered daily to the human being in need thereof. 
     
     
         15 . The method of  claim 1 , wherein compound 1 is administered to the human being once, twice, three times, or four times a day.

Join the waitlist — get patent alerts

Track US2024009178A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.